World’s first non-contact medically approved sleep monitor able to pre-diagnose sleep apnea uses Novelda XeThru sensor technology

With an increasing number of people experiencing sleep related problems, finding home monitoring solutions which also give accurate results has been a challenge. Sleep monitors available today for the general consumer are not precise enough to correctly analyse sleep patterns. Currently the diagnosis of severe sleeping disorders like sleep apnea uses polysomnography (PSG) equipment that is bulky, uncomfortable, and may affect the patient’s sleep quality. Until now, the use of a non-contact method to measure sleep apnea has not been possible.


Shanghai Megahealth has developed the world’s first non-contact sleep monitoring system that not only measures the amount of sleep and its quality, but also the medical parameter Apnea–Hypopnea Index (AHI) that is used to indicate the severity of sleep apnea.

“Finding the right technology partner was critical to our development,” says Wang Jian Jun, COO of Shanghai Megahealth. “We found a few sensor solutions available that can do non-contact vital signs monitoring but they all have severe limitations. Novelda however, with its unique UWB impulse radar sensor technology, has effectively overcome all these limitations. Combined with Megahealth’s own medical-grade hardware system and patented analysis algorithm, the M+ Sleep Monitoring system accurately measures respiration rate, respiration amplitude, whole body movement, sleep time, sleep cycles and AHI.”


In the US, sleep apnea syndrome is estimated to affect about four per cent of men and two per cent of women. The complications of sleep apnea include high blood pressure, heart disease, diabetes, daytime sleepiness as well as difficulty concentrating, thinking and remembering. As AHI is a medical parameter, only medical grade equipment with proven accuracy and safety is allowed to measure this index.

“The fact that Megahealth’s M+ Sleep system built on Novelda’s XeThru sensors has received medical approval is testimony not only to the accuracy of our sensor technology but also to the fact that our radar sensors are 100 per cent safe,” says Bjørn Åge Brandal, Novelda’s VP of sales and marketing in Asia. He continued: “We are very excited to see the first of many non-contact vital signs monitoring solutions enabled by our sensor technology now entering the market.”


The M+ sleep monitoring solution is available now and can be purchased directly from Shanghai Megahealth.

Check Also

Nexperia’s new bipolar junction transistors in DPAK-package deliver high reliability performance for automotive and industrial applications

Nexperia, the expert in essential semiconductors, announced nine new power bipolar transistors, extending its portfolio …